SCHEMBL305290

SCHEMBL305290

N#Cc1cnc(N)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29578164 1.00
SCHEMBL3674005 0.84 CHEK1 (0.44)
SCHEMBL19011572 0.75
SCHEMBL2031652 0.75
SCHEMBL647114 0.74
SCHEMBL26181459 0.73 PDPK1 (0.47)
SCHEMBL16879518 0.72 ATM (0.32)
SCHEMBL24942539 0.72 CHEK1 (0.38)
SCHEMBL610366 0.72
SCHEMBL29413210 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115160522-B Covalent organic framework material and preparation method and application thereof 吉林中科研伸科技有限公司 2023-02-14 CN claimed
CN-115160522-A Covalent organic framework material and preparation method and application thereof 吉林中科研伸科技有限公司 2022-10-11 CN claimed
CN-106866699-A A kind of RTIs of diaryl thienopyrimidines HIV 1 and its preparation method and application 山东大学 2017-06-20 CN claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
US-20260132140-A1 IMIDAZOLYL-AMINO-PYRAZINE-CARBONITRILS AS CHK-1 INHIBITORS BENEVOLENTAI BIO LTD (GB) 2026-05-14 US disclosed
US-12606550-B2 Methods for synthesis of CHK1 inhibitors CRT PIONEER FUND LP (GB) 2026-04-21 US disclosed
US-20260090270-A1 ORGANIC ELECTRONIC ELEMENT AND COMPOUND TOSOH CORPORATION (JP) 2026-03-26 US disclosed
US-12558345-B2 CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas ELI LILLY AND COMPANY (US) 2026-02-24 US disclosed
US-12527790-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof BOUNDLESS BIO, INC. (US) 2026-01-20 US disclosed
US-20260001870-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2026-01-01 US disclosed
US-12492197-B2 3,5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof Impact Therapeutics (Shanghai), Inc (CN) 2025-12-09 US disclosed
US-12448371-B2 Inhibitor compounds Cincera Therapeutics Pty Ltd (AU) 2025-10-21 US disclosed
US-20040147748-A1 5-Substituted-six-membered heteroaromatic glucokinase activators CHEN SHAOQING (US) 2004-07-29 US disclosed
WO-2004052869-A1 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2004-06-24 WO disclosed
CN-1507436-A Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers 2004-06-23 CN disclosed
WO-2004014876-A1 UREA DERIVATIVES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-02-19 WO disclosed
US-20040034038-A1 Urea kinase inhibitors ABBOTT LABORATORIES 2004-02-19 US disclosed
EP-1379510-A1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS ICOS CORPORATION (US) 2004-01-14 EP disclosed
US-20030069284-A1 Compounds useful for inhibiting Chk1 ICOS CORPORATION (A WASHINGTON CORPORATION) 2003-04-10 US disclosed
WO-2002070494-A1 ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS ICOS CORPORATION (US) 2002-09-12 WO disclosed